Sir,
We read and analyzed an article published in your esteemed journal by Giragani et al. [1] First of all, we would like to congratulate the authors on their technical success in endovascular glue embolization of peripheral pulmonary pseudoaneurysms. n-Butyl cyanoacrylate (n-BCA) as an embolizing agent, in our opinion, is a very good embolic agent for permanent occlusion of such pseudoaneurysms. Endovascular embolization is indeed the procedure of choice for the management of these cases and is also the preferred approach at our institute also. However, recently, we have managed pulmonary pseudoaneurysms in our institute using computed tomography or ultrasonography and fluoroscopy guidance to access and percutaneously inject glue (n-BCA), especially in peripherally located pulmonary pseudoaneurysms (6 cases) without having to resort to the endovascular route. We could achieve high technical success and good clinical outcomes and have recently published our experience. [2] Percutaneous glue embolisation has its own advantages such as reduced radiation dose, reduced contrast requirement, shortened procedure time, relative ease of doing procedure, and more economically affordable treatment, especially for patients in developing countries like India. These patients, in our experience, can be managed with a percutaneous approach if they are peripherally located and have good neck-to-dome ratios, favorable anatomical locations for needle placement, and lack of demonstrable high-flow arteriovenous communication. We would like to emphasize that although the endovascular approach is preferred for the management of these patients, a percutaneous glue approach can be used as a primary treatment option for pulmonary pseudoaneurysms in certain patients without need of resorting to endovascular approach.
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